Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare

Ritaccio, Gabrielle; Stoleru, Gianna; Abutaleb, Ameer; Cross, Raymond K.; Shetty, Kirti; Sakiani, Sasan; Wong, Uni

doi:10.1007/s10620-020-06588-6

Cited by 28 publications

(53 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, only a few studies reported the screening of NAFLD in Asian patients with IBD [9,10,[20][21][22], and our study was the first report using CAP technology.…”

Section: Plos Onementioning

confidence: 88%

“…Understanding the underlying causes and predisposing factors of NAFLD among patients with IBD is important to designing therapeutic strategies and improving patient prognosis [ 9 , 14 , 29 ]. The risk of developing NAFLD in the general population is related to diabetes, dyslipidemia, and obesity [ 7 , 21 ]. In patients with IBD, disease-related factors, such as disease duration (mean difference, 1.59 years; 95% CI, 0.66–2.54) and previous intestinal surgery (odds ratio [OR] 1.39; 95% CI, 1.01–1.93), were proposed as precipitating factors for the development of NAFLD [ 9 , 20 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study

Yen

Huang

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

Background/purpose An increased prevalence of non-alcoholic fatty liver disease (NAFLD) is observed in patients with inflammatory bowel disease (IBD) in Western countries. Both intestinal inflammation and metabolic factors contribute to the pathogenesis of IBD-associated NAFLD. The burden of NAFLD is not clear in the Asian population. This study aimed to evaluate the prevalence of NAFLD and liver fibrosis in a cohort of Taiwanese patients with IBD. Methods From January to December 2019, patients with IBD who underwent ultrasound examination were enrolled. Hepatic steatosis and fibrosis were measured with liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) using FibroScan. Patients with a history of excessive alcohol or recent steroid use were excluded. Univariate and multivariate analysis were performed. Results A total of 81 consecutive patients were enrolled and included in the analysis (45 with ulcerative colitis, 36 with Crohn’s disease). The median age was 42 years old. The patients were classified in terms of body mass index as normal weight (54.3%), underweight (11.1%), overweight (28.4%), and obese (6.2%). The mean CAP increased to 162.22 dB/m in the underweight group, 210.86 dB/m in the normal weight group, 260.7 dB/m in the overweight group, and 274.0 dB/m in the obese group. NAFLD was observed in 29.6% of the patients, 1.2% of which had significant fibrosis. Increased body mass index (odds ratio [OR] 1.33, 95% confidence interval [CI] 1.1–1.62) and older age at IBD diagnosis (OR: 1.05, 95% CI 1–1.11) was found to be associated with the presence of NAFLD. Conclusion In this study, the prevalence of NAFLD was lower (29.6%) in IBD patients than in the Western population. Higher BMI and older age were associated with NAFLD in our study.

show abstract

“…To our knowledge, only a few studies reported the screening of NAFLD in Asian patients with IBD [9,10,[20][21][22], and our study was the first report using CAP technology.…”

Section: Plos Onementioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study

Yen

Huang

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…In this issue of Digestive Diseases and Sciences, Ritaccio et al [6] report their findings on the prevalence of NAFLD and trends in the progression of NAFLD-associated fibrosis among patients with IBD. In a large population of 1672 patients with IBD seen at a tertiary-care academic center, 14% had radiologic or biopsy-proven evidence of hepatic steatosis.…”

mentioning

confidence: 99%

“…Recent research has highlighted the notable prevalence of NAFLD among patients with IBD, as well as the potential interactions between these two diseases. Ritaccio and colleagues [6] take the further step to investigate the clinical implications of NAFLD in IBD. They provided important and reassuring data that most patients have low-intermediate fibrosis that largely remains stable over 5 years.…”

mentioning

confidence: 99%

Arrested Development: Slow Progression of Fibrosis in Patients with NAFLD and IBD

Jeon

Limketkai

2020

Dig Dis Sci

View full text Add to dashboard Cite

“…However, whether IBD can promote NASH development remains controversial. It has been reported that patients with IBD have a higher incidence of NAFLD (Magrì et al, 2019;Ritaccio et al, 2020). NAFLD accounts for up to 40.8% of the hepatic alterations in patients with IBD that do not have metabolic risk factors (Gisbert et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Table_1.XLSX

View full text Add to dashboard Cite

Nonalcoholic Fatty Liver Disease Is Common in IBD Patients However Progression to Hepatic Fibrosis by Noninvasive Markers Is Rare

Cited by 28 publications

References 14 publications

Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study

Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study

Arrested Development: Slow Progression of Fibrosis in Patients with NAFLD and IBD

Table_1.XLSX

Contact Info

Product

Resources

About